As of Jan 25
| 0.00 / 0.00%|
Immunoclin Corp. is a healthcare company. The company is focused on developing preventive medicines to fight inflammatory conditions that are the cause of pathologies in conditions affecting the majority of the human population such as infections, cancer, cardiovascular disease and dementia, including Alzheimer's disease. Its products include Multi-Variant Atherosclerosis Risk Assessment, an algorithm to analyze the multi variant data to identify people who are at risk of having heart attack; Genetic Alzheimer's Risk Discovery, a genetic test for multiple genetic variants associated with risk of the common form of dementia, Alzheimer disease; PRIMALEUKIN, commonly known as interleukin-22, has a position as a combined antibacterial, anti-fungal and antiviral agent, harnessing and amplifying the body's own natural defense against, and recovery from infection;and DACTELLIGENCE Technology, a technology to engineer a sensor using a mathematically modeled fractal dactyl surface creating confined cages. Immunoclin was founded on February 8, 2011 and is headquartered in Washington, DC.
|Dorothy H. Bray||President, Chief Executive Officer & Director|
|Chad S. Johnson||COO, Secretary, Director & General Counsel|
|James Scott Munro||CFO, Treasurer & Principal Accounting Officer|
|Khadija Benlhassan||Director & Chief Scientific Officer|